Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1001 oversight story
BioCentury & Getty Images

Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

Oct 1, 2020 | 10:32 PM GMT

During the second and final day of a drug pricing hearing, Democratic members of the House Oversight and Reform Committee again pounded pharma CEOs, accusing them of taking unjustified price increases and engaging in anti-competitive activities.

The hearing continued themes

Read the full 651 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE